Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Dayton, OH
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Dayton, OH
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Mentor, OH
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Mentor, OH
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Greenville, SC
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Rapid City, SD
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Bristol, TN
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Bristol, TN
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Chattanooga, TN
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Germantown, TN
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Germantown, TN
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Arlington, TX
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Arlington, TX
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Austin, TX
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Spring, TX
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Spring, TX
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Bountiful, UT
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Bountiful, UT
Click here to add this to my saved trials
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Norfolk, VA
A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Birmingham, AL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Tucson, AZ
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
North Little Rock, AR
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
North Little Rock, AR
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
La Jolla, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
La Jolla, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Pasadena, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Sacramento, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
San Clemente, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
San Clemente, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
San Francisco, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Santa Clara, CA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Englewood, CO
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Englewood, CO
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Washington,
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Miami, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Sarasota, FL
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Marietta, GA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Honolulu, HI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Iowa City, IA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Worcester, MA
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Worcester, MA
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Detroit, MI
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Binghamton, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Binghamton, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Manhasset, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Manhasset, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
New York, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Syracuse, NY
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Syracuse, NY
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Durham, NC
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Cleveland, OH
Click here to add this to my saved trials
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated:  11/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy
Status: Enrolling
Updated: 11/8/2017
GSK Investigational Site
mi
from
Tulsa, OK
Click here to add this to my saved trials